ArticlemedRxiv : the preprint server for health sciences2025
Assessing Cognitive Decline and Dementia Risk in Black and White Older Adults with Blood Biomarkers pTau217, GFAP, NfL, and Aβ ratio.
Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Alzheimer's disease blood-based biomarkers are a cost-effective early-detection method that, for precision medicine reasons, needs to be studied in both Blackand White. Few studies have a long follow-up of cognition. We studied a blood-biomarkers panel, cognitive decline, and dementia risk in a large number of Black and White participants. Methods: Participants without dementia were followed annually up to 15 years, after plasma biomarker measurement (NfL, GFAP, amyloid-beta 42/40 ratio, pTau217). Data included demographics, medical history, blood tests (e.g., kidney function), MMSE, APOEε4, annual evaluations of cognition, and clinician-based dementia evaluation. The biomarkers' association with comorbidities, cognitive decline, and risk of dementia was examined within race. To examine racial differences, we repeated analyses using a subset Mahalanobis-balanced 1:1 on sex, age, education, Latino/Non-Latino, and clinical status (hypertension, diabetes, GFR, BMI, and heart disease). Results: Biomarkers were measured in 431 Black and 583 White (respectively mean age of 77 and 80, 17% and 21% men), generating a balanced sample of 366:366. Biomarker's levels were similar between races. Within races, the associations of blood biomarkers with multiple comorbidities (especially kidney dysfunction and BMI) remained after controlling for demographics, APOE ε4, and dementia or death within 5 years. Men had lower GFAP levels than women (all p=<0.001). pTau217 was associated with decline in global cognition and all domains within races, and when comparing races, it was associated with a faster decline in global cognition and semantic memory in Black. The discrimination of dementia of pTau217 (AUC Discussion: pTau217 was highly associated with dementia risk and cognitive decline. The association of blood biomarkers with cognitive decline in Black and White participants was similar. Higher levels of pTau217 were, however, associated with semantic memory decline in Black adults. The combination of pTau217 with other biomarkers or MMSE did not improve dementia discrimination.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.